Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis

Clicks: 187
ID: 274324
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #11 of 17 articles by views in The primary care companion for CNS disorders

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Given the scarcity of data, the authors of this review systematically synthesized the literature to determine the long-term efficacy and safety of aripiprazole as a maintenance augmenting agent for major depressive disorder. Read on to find out more.
Reference Key
seshadri2021thelong-term Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ashok Seshadri;Michaela E. Wermers;Timothy J. Habermann;Balwinder Singh;
Journal The primary care companion for CNS disorders
Year 2021
DOI
DOI not found
URL
https://www.psychiatrist.com/pcc/depression/long-term-efficacy-tolerability-adjunctive-aripiprazole-major-depressive-disorder/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.